(Press-News.org) Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) to be published in the journal Nature Medicine. “Even though there are several options on the market, the reality is that semaglutide and tirzepatide are so effective that they should be the first choice in almost all cases,” says co-first author Dr Andreea Ciudin.
The authors are an international team of obesity experts led by the co-chairs of the EASO Obesity Management Working Group who are Dr Andreea Ciudin, Vall d’Hebron University Hospital, Autonomous University Barcelona, Barcelona, Spain; Professor Barbara McGowan, Guys & St Thomas‘s Hospital NHS Foundation Trust, London, UK; and a team including EASO President Professor Volkan Yumuk, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Turkey, and colleagues.
The number of medications available to treat obesity and its complications has been steadily increasing in recent years and is expected to continue growing, offering clinicians a wider selection of agents with distinct modes of action to be used alongside lifestyle interventions. As different medications vary in their efficacy for total weight loss and their effects on obesity-related complications, personalised therapy based on individual patient characteristics has become both feasible and necessary.
In this new algorithm for obesity management medication published by EASO, the authors used the presence or absence of obesity-related complications as the primary factor to guide the strategy for selecting the treatment. Each individual medication was therefore evaluated based on its effectiveness in promoting total weight loss, its impact on complications, and its safety profile. “It is the first framework guided by the presence or absence of obesity-related complications, since weight loss is not the only goal of treatment when complications are present,” explains Professor McGowan.
Although still relatively recently approved for obesity treatment, the evidence base for both semaglutide (a glucagon-like peptide-1 [GLP-1] receptor agonist) and tirzepatide (a dual gastric inhibitory polypeptide [GIP] and GLP-1 receptor agonist) has been building rapidly.
The authors concluded on the basis of the results of clinical trials included in the traditional and network meta-analyses, tirzepatide and semaglutide should be considered the medications of choice when a substantial total body weight loss is required. When a lesser degree of weight loss is the target, other medications can be considered, including liraglutide, naltrexone–bupropion, and phentermine-topiramate.
When looking at complications, the authors separated their analysis aligned with the conceptual distinction between fat mass disease (more prone to mechanical complications) and sick fat disease (more prone to immunological and metabolic complications). But, regardless of this distinction, again semaglutide and/or tirzepatide were the first-line recommendations in each case.
For so-called fat mass diseases, tirzepatide is the first line treatment recommended for people living with obesity and obstructive sleep apnoea (OSA), although this is based on only one randomised clinical trial (RCT) at present. For people living with obesity and knee osteoarthritis, the only RCTs available show semaglutide to be the most effective treatment for pain reduction, so semaglutide is recommended as the first line treatment.
In the sick-fat disease category, four diseases were analysed (due to the evidence available at the time) – prediabetes and type 2 diabetes; cardiovascular disease; heart failure; and metabolic dysfunction associated steatotic liver disease (MASH). For people living with obesity and prediabetes and type 2 diabetes, tirzepatide and semaglutide should be prescribed as first-choice medications and liraglutide and naltrexone–bupropion as second-line treatments in individuals with obesity and abnormal blood sugar profiles. For people living with obesity and cardiovascular disease, the authors’ meta-analysis has shown a significant reduction in the incidence of major adverse cardiovascular events (MACE) in individuals with previous cardiovascular events treated with semaglutide – and thus recommend semaglutide as the first line treatment.
For those living with obesity and heart failure, the authors note that more data are required, but current evidence suggests either tirzepatide or semaglutide should be considered first-line treatments in patients with heart failure. For people living with obesity and MASH, at present, the authors recommend the use of tirzepatide as first line treatment, but note the phase 3 ESSENCE trial, not included in the present algorithm because it was published after 31 January, 2025, showed that semaglutide was associated with a significant improvement in MASH and liver fibrosis similar to tirzepatide. Thus future updates to the algorithm are likely to include recommending semaglutide as a first line treatment for people with obesity and MASH.
The authors also note the complex economic considerations, different in each national context, that these new medications including semaglutide and tirzepatide, collectively known as incretins, are causing - but say that “the cost of not treating obesity and adipose tissue dysfunction at early stages — thus enabling the progression to complications and end-organ damage —should be weighed equally in health policy and clinical decision-making”.
Summarising the algorithm, the authors say: “It is important to note that most medications have not been specifically evaluated for the treatment of individual complications, resulting in gaps in our understanding of their full therapeutic potential. Although some benefits may be inferred based on the degree of total body weight loss — given the well-documented positive effect of total weight loss on various complications — direct evidence for many conditions remains limited. Nevertheless, there is growing potential for medications to positively influence a broader range of complications, including chronic kidney disease, neurodegenerative disorders, polycystic ovary syndrome, certain cancers, and mental health conditions.”
Professor McGowan says: “Tailoring treatment to the individual is a complex task that must consider several factors, including the severity of adiposity, the presence and extent of complications, comorbidities and concurrent therapies. Socioeconomic context, patient values, expectations, and personal goals must also be considered.”
Dr Ciudin says: “Although no treatment algorithm can replace the nuanced clinical judgment required for such comprehensive assessments, this tool can serve to support therapeutic decision-making in obesity.” She adds: “This new class of GLP-1 agonists and GIP/GLP-1 dual agonists is completely transforming care of obesity and its complications.”
And Prof Yumuk concludes: “Given the rapid advances in the field of medications to treat obesity, EASO intends to update the present treatment algorithm regularly to incorporate the latest available evidence.”
END
Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO)
2025-10-02
ELSE PRESS RELEASES FROM THIS DATE:
Generative AI is more efficient than nature at designing proteins to edit the genome
2025-10-02
Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life Sciences (MELIS) and the Center for Genomic Regulation (CRG), have designed and experimentally validated new synthetic proteins that can edit the human genome more efficiently than proteins provided by nature. This work, a global pioneer published today in the journal Nature Biotechnology, will be of great use in improving the current gene editing tools used in biotechnology research and personalized medicine by developing cellular (CAR-T) and gene therapies, especially to treat ...
ESMT Berlin study: ESG ratings show limited financial impact in the Gulf
2025-10-02
Firms in the Gulf region are increasingly expected to align with environmental, social, and governance (ESG) standards. Yet the link between ESG performance and financial outcomes remains ambiguous. A new study examines whether publicly listed companies in GCC member states that achieve high ESG ratings also deliver superior financial performance.
The study “ESG and financial performance in the Gulf Cooperation Council” was authored by Catalina Stefanescu-Cuntze, professor of management science and faculty lead of the Master in Analytics and Artificial Intelligence Program at ESMT Berlin, together with Rodrigo Tavares and Catarina Sá from Nova School ...
Scalable AI tracks motion from single molecules to wildebeests
2025-10-02
University of Michigan researchers have developed a tool powered by artificial intelligence that can help them examine the behavior of a single molecule out of a sea of information in the blink of an eye—or at least overnight.
Understanding the behavior of single molecules is important: it can lead to knowledge of different cellular processes or track how diseases begin and progress. To track the behavior of single molecules, researchers tag the molecules with what's called a fluorophore. They excite these fluorophores with a laser, then use powerful microscopes to follow the behavior of the tagged molecules over time.
But ...
Viewing teens more positively may help their school performance and strengthen family bonds
2025-10-02
Western cultures tend to view teens as moody, irresponsible, and rebellious. However, in China and in other cultures, the teen years are viewed more positively and seen as a time of learning how to become responsible and fulfilling family obligations. Previous research shows that fulfilling family obligations is an important marker of maturity and that as adolescents continue to improve their skills, they can contribute more to their families.
Past studies also show that when teens are seen ...
Antarctic Sea ice emerges as key predictor of accelerated ocean warming
2025-10-02
A groundbreaking study published today in the European Geosciences Union (EGU) journal Earth System Dynamics provides a critical and previously underestimated connection between Antarctic sea ice, cloud cover, and global warming. This research is important because it shows that a greater extent of Antarctic sea ice today, compared to climate model predictions, means we can expect more significant global warming in the coming decades.
The study, led by Linus Vogt from Sorbonne University, utilized an emergent constraint based on data from 28 Earth system models and satellite observations ...
Researchers discover air pollution particles hitching a ride around the body on red blood cells
2025-10-02
Researchers have found the first direct evidence that tiny particles of air pollution stick to our red blood cells, meaning they can travel freely around the body.
These particles are produced by vehicle exhausts and from brake and tyre wear, and can easily enter the lungs. They have recently been found in the brain and heart, where they are linked to increased risk of disease. However, until now, there has been no conclusive evidence of how pollution particles infiltrate these parts of the body.
In the ...
The importance of a leader–follower relationship for performing tasks
2025-10-02
As most of us have experienced, when multiple people work together, things sometimes turn out better than doing the same task alone. Then, there are the other times, when cooperation actually seems to hinder progress, making things much more inefficient.
To understand why this ‘cooperative advantage’ manifests in some cases but not in others, a research group led by Assistant Professor Asuka Takai of the Graduate School of Engineering at Osaka Metropolitan University conducted a task where participants used a robotic arm ...
The Crown Princess of Sweden honoured with a professorship in biodiversity
2025-10-02
The University of Gothenburg is establishing the Crown Princess Victoria Professorship in Biodiversity. The professorship is a gift ahead of the Crown Princess's 50th birthday in 2027, in collaboration between Carl Bennet AB and the University of Gothenburg.
Biodiversity is a growing field of research, and the University of Gothenburg now has the opportunity to contribute more effectively through a new professorship in biodiversity established in the Crown Princess's name. The Crown Princess has repeatedly expressed her belief that the diversity ...
Revolutionary skin sensing technology set to transform eczema and psoriasis treatment
2025-10-02
A groundbreaking technology developed by Heriot-Watt University has received over £475,000 in funding to revolutionise how eczema is diagnosed and treated, potentially ending years of suffering for millions of patients across the UK.
The innovative vibroacoustic sensor, which measures material changes in each layer of skin using small vibrations on the surface, has received £275,000 from Scottish Enterprise and just over £200,000 from the Medical Research Council's Gap Fund to advance clinical ...
Commercial sunbeds should be banned in the UK, say experts
2025-10-01
Commercial sunbeds should be banned in the UK, argue experts in The BMJ today.
Using sunbeds causes melanoma and other skin cancers, particularly among young people, yet existing sunbed legislation is ineffective and there is little evidence that stricter rules would help protect the most vulnerable, say Professor Paul Lorigan and colleagues.
Indoor tanning is experiencing a boom in popularity, particularly among Gen Z (born 1997-2012), with social media promoting sunbeds as integral to wellness, they explain. For example, a 2024 survey of 2,003 people in the UK by Melanoma Focus ...